Acute coronary syndrome (ACS) is a group of clinical syndromes caused by acute myocardial ischemia on the basis of coronary atherosclerosis. Antithrombotic therapy plays an important role in ACS. Antithrombotic therapy mainly includes antiplatelet therapy and antithrombin therapy. For non-ST elevation ACS (NSTE-ACS), antithrombotic therapy can prevent further development of thrombosis and avoid further necrosis of ischemic myocardium. Antithrombotic therapy can enhance the recanalization effect of thrombolytic agents, reduce the re-occlusion or re-infarction after thrombolysis or primary PCI, improve both short-term and long-term prognosis of ACS patients, and reduce mortality. Therefore, we hope to find the best strategy of antithrombotic therapy for ACS.
In this Research Topic, we would like to create a forum for current advances on for the pathological and physiological mechanisms of thrombosis in ACS, as well as the latest development of antithrombotic drug and device treatment strategies, to provide more evidence-based medicine for antithrombotic treatment of ACS.
The subtopics of interest include, but are not limited to:
1) New biomarkers to optimize antithrombotic strategy for ACS.
2) Invasive imaging tests as the auxiliary decision-making of optimal antithrombotic treatment for ACS.
3) Clinical likelihood of mono-antiplatelet protocol with strong P2Y12 inhibitor after PCI in low or intermediate risk ACS patients.
4) Combinational antithrombotic protocol with NOAC plus strong P2Y12 inhibitor (Ticagrelor or Prasugrel) in high-risk ischemic ACS patients with atrial fibrillation.
5) The latest development of antithrombotic drug or device for ACS.
6) Individualized antithrombotic therapy optimization with Artificial Intelligence (e.g. machine learning)
7) The optimal antithrombotic protocol in elderly patients over 75yrs with ACS.
8) The optimal antithrombotic duration in ACS patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).
9) The optimal antithrombotic protocol and duration in ACS patients receiving drug-eluting-balloon angioplasty.
Acute coronary syndrome (ACS) is a group of clinical syndromes caused by acute myocardial ischemia on the basis of coronary atherosclerosis. Antithrombotic therapy plays an important role in ACS. Antithrombotic therapy mainly includes antiplatelet therapy and antithrombin therapy. For non-ST elevation ACS (NSTE-ACS), antithrombotic therapy can prevent further development of thrombosis and avoid further necrosis of ischemic myocardium. Antithrombotic therapy can enhance the recanalization effect of thrombolytic agents, reduce the re-occlusion or re-infarction after thrombolysis or primary PCI, improve both short-term and long-term prognosis of ACS patients, and reduce mortality. Therefore, we hope to find the best strategy of antithrombotic therapy for ACS.
In this Research Topic, we would like to create a forum for current advances on for the pathological and physiological mechanisms of thrombosis in ACS, as well as the latest development of antithrombotic drug and device treatment strategies, to provide more evidence-based medicine for antithrombotic treatment of ACS.
The subtopics of interest include, but are not limited to:
1) New biomarkers to optimize antithrombotic strategy for ACS.
2) Invasive imaging tests as the auxiliary decision-making of optimal antithrombotic treatment for ACS.
3) Clinical likelihood of mono-antiplatelet protocol with strong P2Y12 inhibitor after PCI in low or intermediate risk ACS patients.
4) Combinational antithrombotic protocol with NOAC plus strong P2Y12 inhibitor (Ticagrelor or Prasugrel) in high-risk ischemic ACS patients with atrial fibrillation.
5) The latest development of antithrombotic drug or device for ACS.
6) Individualized antithrombotic therapy optimization with Artificial Intelligence (e.g. machine learning)
7) The optimal antithrombotic protocol in elderly patients over 75yrs with ACS.
8) The optimal antithrombotic duration in ACS patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).
9) The optimal antithrombotic protocol and duration in ACS patients receiving drug-eluting-balloon angioplasty.
